甲状腺癌
下调和上调
癌症研究
小RNA
甲状腺癌
基因沉默
甲状腺乳突癌
肿瘤进展
癌变
癌症
甲状腺
医学
生物
内科学
基因
生物化学
作者
Su Dong,Shuai Xue,Yue Sun,Zhe Han,Lele Sun,Jialu Xu,Jia Liu
出处
期刊:Journal of Investigative Medicine
[BMJ]
日期:2021-01-01
卷期号:69 (1): 66-74
被引量:16
标识
DOI:10.1136/jim-2020-001562
摘要
MicroRNA-363-3 p (miR-363–3 p) has been reported to play a crucial role in tumor development and progression, and function as a tumor suppressor in many types of cancer. In our previous studies, we found that miRNA-363–3 p inhibited papillary thyroid carcinoma (PTC) progression by targeting PIK3CA. Meanwhile, we found that NIN1/RPN12 binding protein 1 (NOB1) was significantly upregulated in thyroid carcinoma tissue and downregulation of NOB1 expression significantly inhibited cell proliferation, migration and invasion in PTC. However, the correlation of NOB1 and miR-363–3 p has not been investigated. Here, we performed bioinformatic analysis to explore miRNA targeting NOB1. We found that NOB1 was a target of miR-363–3 p and miR-363–3 p regulated NOB1 expression at the translational and transcriptional levels by targeting its 3’ untranslated region (3′-UTR). Further, we showed that miR-363–3 p inhibited tumor progression by targeting NOB1 in vitro and in vivo. We found that overexpression miR-363–3 p or silencing NOB1 significantly increased G0/G1-phase and decreased S-phase in the human papillary thyroid cells, which led to a significant delay in cell proliferation, indicating miR-363–3 p and NOB1 are crucial for human papillary thyroid cancer tumorigenesis. Collectively, our data unveil that miR-363–3 p negatively regulates NOB1 activity by reducing its stability. This study provides a new therapeutic target for regulation of NOB1 stability to modulate human papillary thyroid cancer progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI